Surface Oncology Gross Profit

The latest gross profit for SURF is $30M as of June 2023. That compares with $31M in the prior-year period — down 1.8% year over year. That is below the Healthcare sector average of $66B. Investors often review this figure alongside Surface Oncology's historical trend and sector peers before judging valuation or financial health.

Over the past year, SURF's gross profit moved from $31M to $30M — a 1.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Surface Oncology's operating scale or balance-sheet position.

Against Healthcare companies, SURF currently prints $30M for gross profit, while the sector average sits near $66B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Surface Oncology's growth, margins, and balance sheet.

A gross profit figure of $30M for SURF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $66B. Explore the charts below for those layers of context.

After noting SURF's gross profit ($30M), review year-over-year change from $31M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.